HbA1c is widely used biomarker for the diagnosis and prognosis for diabetes, as well as monitoring for blood glucose level over the previous three months before the measurement. Biohermes A1C EZ 2.0 Glycohemoglobin Analysis System utilizes boronate affinity lateral chromatography method to determine hemoglobin A1c percentage in human blood sample.
HbA1c, formed in a non-enzymatic glycation pathway by hemoglobin’s exposure to plasma glucose, reflects average glycemia over several months.
As a primary technique to assess the effectiveness of diabetes management, HbA1c has strong predictive value for diabetes complications. Lowering HbA1C has been shown to reduce complications.
HbA1c ≥6.5% (48 mmol/mol) is one of the criteria for diabetes diagnosis. Normal HbA1c range is 4.0-5.7% (20-39 mmom/mol), while 5.7-6.4% (39-46 mmol/mol) is considered as prediabetes.
Point-of-care testing for HbA1c provides the opportunity for more timely treatment changes.